Liang Zhang

机构：Capital Medical University, Beijing Ditan Hospital · ORCID：0009-0002-3894-2848

发表论文 72 篇 · 总被引 2024 次 · h-index 23

代表论文

• Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials (2022 · The Lancet Respiratory Medicine · 被引 145)
• Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects (2024 · Signal Transduction and Targeted Therapy · 被引 68)
• Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters (2023 · Nature Communications · 被引 58)
• Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial (2022 · EClinicalMedicine · 被引 39)
• Interleukin‐6 promotes skeletal muscle catabolism by activating tryptophan–indoleamine 2,3‐dioxygenase 1–kynurenine pathway during intra‐abdominal sepsis (2023 · Journal of Cachexia Sarcopenia and Muscle · 被引 28)
• Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels (2024 · Journal of Hepatology · 被引 21)